Mainz Biomed B.V.

NasdaqCM MYNZ

Mainz Biomed B.V. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2023: USD -21.94 M

Mainz Biomed B.V. Operating Cash Flow is USD -21.94 M for the Trailing 12 Months (TTM) ending December 31, 2023, a -48.54% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Mainz Biomed B.V. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2022 was USD -14.77 M, a -199.79% change year over year.
Mainz Biomed B.V. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2021 was USD -4.93 M, a -951.06% change year over year.
Mainz Biomed B.V. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2020 was USD -468.74 K.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: MYNZ

Mainz Biomed B.V.

CEO	Mr. Guido Baechler
IPO Date	Nov. 5, 2021
Location	Germany
Headquarters	Robert Koch Strasse 50
Employees	65
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Key trends

Past 5 years